CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.

Liwen RenYihui YangWan LiXiangjin ZhengJinyi LiuSha LiHong YangYizhi ZhangBinbin GeSen ZhangWeiqi FuDexin DongGuanhua DuJinhua Wang

Published in: Journal of translational medicine (2022)

CDK1 could be exploited as an essential therapeutic target of ACC via regulating the EMT, the G2/M checkpoint, and PANoptosis. Thus, CurE may be a potential candidate drug for ACC therapy with good safety and efficacy, which will meet the great need of patients with ACC.

Keyphrases

epithelial mesenchymal transition
cell cycle
transforming growth factor
signaling pathway
dna damage
emergency department
human health
risk assessment
oxidative stress
bone marrow